ThermoGenesis said it has received approval in China to distribute its AXP AutoXpress for the processing of stem cells from umbilical cord blood. "This is a major milestone for the company as a first mover in China for the automation of cord blood processing and presents a significant catalyst for the growth of our cord blood business," chief executive Matthew Plavan said.

Related Summaries